Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Pieper

Showing results (201-210 of 223) with videos related to

Pageof 23
Sort By:
Journal of the American Heart Association|March 10, 2016
Cause of Death and Predictors of All-Cause Mortality in Anticoagulated Patients With Nonvalvular Atrial Fibrillation: Data From ROCKET AFSean D Pokorney, Jonathan P Piccini, Susanna R Stevens, et al.
Clinical Cardiology|August 19, 2023
Predictors of intracranial hemorrhage in patients with atrial fibrillation treated with oral anticoagulants: Insights from the GARFIELD-AF and ORBIT-AF registriesToon Wei Lim, Alan John Camm, Saverio Virdone, et al.
Heart (British Cardiac Society)|February 17, 2021
Comparative effectiveness of oral anticoagulants in everyday practiceA John Camm, Keith A A Fox, Saverio Virdone, et al.
Circulation|December 28, 2018
Early Risks of Death, Stroke/Systemic Embolism, and Major Bleeding in Patients With Newly Diagnosed Atrial FibrillationJean-Pierre Bassand, Saverio Virdone, Samuel Z Goldhaber, et al.
Circulation. Arrhythmia and Electrophysiology|December 14, 2019
Outcomes and Anticoagulation Use After Catheter Ablation for Atrial FibrillationJames V Freeman, Peter Shrader, Karen S Pieper, et al.
BMJ Open|December 24, 2017
Improved risk stratification of patients with atrial fibrillation: an integrated GARFIELD-AF tool for the prediction of mortality, stroke and bleed in patients with and without anticoagulationKeith A A Fox, Joseph E Lucas, Karen S Pieper, et al.
American Heart Journal|February 22, 2025
Oral factor xia inhibitor milvexian after a recent acute coronary syndrome: Rationale and design of the phase 3 (Librexia ACS)C Michael Gibson, M Cecilia Bahit, Roxana Mehran, et al.
Heart Rhythm O2|January 2, 2023
Residual stroke risk despite oral anticoagulation in patients with atrial fibrillationMatthew A Carlisle, Peter Shrader, Marat Fudim, et al.
American Heart Journal|May 26, 2019
Predictors of NOAC versus VKA use for stroke prevention in patients with newly diagnosed atrial fibrillation: Results from GARFIELD-AFSylvia Haas, A John Camm, Jean-Pierre Bassand, et al.
Healthcare (Basel, Switzerland)|March 11, 2023
Healthcare Resource Utilization in Patients with Newly Diagnosed Atrial Fibrillation: A Global Analysis from the GARFIELD-AF RegistryLorenzo G Mantovani, Paolo Cozzolino, Pietro Ferrara, et al.
Pageof 23

Showing results (201-210 of 223) with videos related to

Sort By:
Pageof 23
Journal of the American Heart Association|March 10, 2016
Cause of Death and Predictors of All-Cause Mortality in Anticoagulated Patients With Nonvalvular Atrial Fibrillation: Data From ROCKET AFSean D Pokorney, Jonathan P Piccini, Susanna R Stevens, et al.
Clinical Cardiology|August 19, 2023
Predictors of intracranial hemorrhage in patients with atrial fibrillation treated with oral anticoagulants: Insights from the GARFIELD-AF and ORBIT-AF registriesToon Wei Lim, Alan John Camm, Saverio Virdone, et al.
Heart (British Cardiac Society)|February 17, 2021
Comparative effectiveness of oral anticoagulants in everyday practiceA John Camm, Keith A A Fox, Saverio Virdone, et al.
Circulation|December 28, 2018
Early Risks of Death, Stroke/Systemic Embolism, and Major Bleeding in Patients With Newly Diagnosed Atrial FibrillationJean-Pierre Bassand, Saverio Virdone, Samuel Z Goldhaber, et al.
Circulation. Arrhythmia and Electrophysiology|December 14, 2019
Outcomes and Anticoagulation Use After Catheter Ablation for Atrial FibrillationJames V Freeman, Peter Shrader, Karen S Pieper, et al.
BMJ Open|December 24, 2017
Improved risk stratification of patients with atrial fibrillation: an integrated GARFIELD-AF tool for the prediction of mortality, stroke and bleed in patients with and without anticoagulationKeith A A Fox, Joseph E Lucas, Karen S Pieper, et al.
American Heart Journal|February 22, 2025
Oral factor xia inhibitor milvexian after a recent acute coronary syndrome: Rationale and design of the phase 3 (Librexia ACS)C Michael Gibson, M Cecilia Bahit, Roxana Mehran, et al.
Heart Rhythm O2|January 2, 2023
Residual stroke risk despite oral anticoagulation in patients with atrial fibrillationMatthew A Carlisle, Peter Shrader, Marat Fudim, et al.
American Heart Journal|May 26, 2019
Predictors of NOAC versus VKA use for stroke prevention in patients with newly diagnosed atrial fibrillation: Results from GARFIELD-AFSylvia Haas, A John Camm, Jean-Pierre Bassand, et al.
Healthcare (Basel, Switzerland)|March 11, 2023
Healthcare Resource Utilization in Patients with Newly Diagnosed Atrial Fibrillation: A Global Analysis from the GARFIELD-AF RegistryLorenzo G Mantovani, Paolo Cozzolino, Pietro Ferrara, et al.
Pageof 23